Inflexal®V a trivalent virosome subunit influenza vaccine:: production
Inflexal®V a trivalent virosome subunit influenza vaccine:: production
复制标题
DOI：
10.1016/s0264-410x(02)00512-1
复制
发表时间：
2002-12-20
期刊：
影响因子：
5.5
通讯作者：
Metcalfe, IC
中科院分区：
文献类型：
--
作者：
Mischler, R;Metcalfe, IC
Infleal(R)V是一种新型的基于病毒体的三价流感疫苗，已被证明具有高度的免疫原性，在儿童、年轻人和老年人中具有良好的耐受性。在这里，我们讨论Infleal(R)V的制造技术，强调制造过程的纯度和一致性。在构建Infleal(R)V时要考虑的关键因素是保留抗原的自然呈现、其生物降解性和很少出现不良事件。疫苗的成分也根据人类使用的适宜性、辅助性和天生的无毒性进行了仔细的考虑。(C)2002爱思唯尔科学有限公司。保留所有权利。
Inflexal(R)V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in children, young adults, and the elderly. Here we discuss the techniques for the manufacture of Inflexal(R)V, highlighting the purity and consistency of the manufacturing process. Key factors to be taken into account in the construction of Inflexal(R)V are the retention of the natural presentation of antigens, its biodegradability and the presentation of few adverse events. The constituents of the vaccine were also carefully considered based on suitability for human use, adjuvanticity and an innate lack of toxicity. (C) 2002 Elsevier Science Ltd. All rights reserved.